RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2
Keyword(s):
Phase Ii
◽
2015 ◽
Vol 33
(15_suppl)
◽
pp. 4547-4547
◽
2009 ◽
Vol 27
(5)
◽
pp. 572
2011 ◽
Vol 29
(15_suppl)
◽
pp. e15118-e15118
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. 4565-4565
◽